Layoffs Have Begun

Quote
There is anti-white racism disguised as DEI going on at Merck.

There have been several instances where Indian managers have laid off whites telling them that their position was eliminated but than gave the job to other Indians.

If you go into building 34 is probably 80% Indian.
 




































If they downsize it had better be the right people. Never seen a company with so much ambiguity, overlapping and overcrowding in the new and shiny space. It’s like no one really understands their own JD and hops on the next fancy bus that comes along. Every other meeting is crowded with free riders. The company has probably 50% of workforce doing the work of the remaining and performance management are now skewed towards behaviours rather than actual decisions that benefit for the company or patients. That explains the surplus of improvement projects that fails and gets scrapped within a year or two. What a waste of money and resources!
 






anonymous said:
If they downsize it had better be the right people. Never seen a company with so much ambiguity, overlapping and overcrowding in the new and shiny space. It’s like no one really understands their own JD and hops on the next fancy bus that comes along. Every other meeting is crowded with free riders. The company has probably 50% of workforce doing the work of the remaining and performance management are now skewed towards behaviours rather than actual decisions that benefit for the company or patients. That explains the surplus of improvement projects that fails and gets scrapped within a year or two. What a waste of money and resources!
Click to expand...
Managers are wasting too much time playing suck ups than to do actual job - thankfully enabled by surplus coming from Keytruda. Flying the plane while building it is probably one of the most nonsensical quote sold to us. They are not interested to do the right things at the start and would rather waste time and resources patching up on the backend after rolling out to impress the higher ups. Low quality work wrap with pretty packagings and ribbons. Pathetic.
 






anonymous said:
Managers are wasting too much time playing suck ups than to do actual job - thankfully enabled by surplus coming from Keytruda. Flying the plane while building it is probably one of the most nonsensical quote sold to us. They are not interested to do the right things at the start and would rather waste time and resources patching up on the backend after rolling out to impress the higher ups. Low quality work wrap with pretty packagings and ribbons. Pathetic.
Click to expand...
anonymous said:
If they downsize it had better be the right people. Never seen a company with so much ambiguity, overlapping and overcrowding in the new and shiny space. It’s like no one really understands their own JD and hops on the next fancy bus that comes along. Every other meeting is crowded with free riders. The company has probably 50% of workforce doing the work of the remaining and performance management are now skewed towards behaviours rather than actual decisions that benefit for the company or patients. That explains the surplus of improvement projects that fails and gets scrapped within a year or two. What a waste of money and resources!
Click to expand...
My experience from the last year is that the people that get the work done and moving forward efficiently are being let go. The suck ups are being kept, or the work is being outsourced overseas to folks that deliver very subpar deliverables but for super cheap. It’s like Temu Pharma. But it cuts the bottom line, which is the only thing higher ups seem focused on.

And like always, this pendulum will swing back and there will be more focus on qualified people and work only after bad Inspection/ recall. Although I guess US sites may be less at risk given the chaos at FDA these days. Historically they were the hardest on our sites.
 






anonymous said:
My experience from the last year is that the people that get the work done and moving forward efficiently are being let go. The suck ups are being kept, or the work is being outsourced overseas to folks that deliver very subpar deliverables but for super cheap. It’s like Temu Pharma. But it cuts the bottom line, which is the only thing higher ups seem focused on.

And like always, this pendulum will swing back and there will be more focus on qualified people and work only after bad Inspection/ recall. Although I guess US sites may be less at risk given the chaos at FDA these days. Historically they were the hardest on our sites.
Click to expand...
Good job FDA! Perhaps we need another consent decree.
 






























anonymous said:
Managers are wasting too much time playing suck ups than to do actual job - thankfully enabled by surplus coming from Keytruda. Flying the plane while building it is probably one of the most nonsensical quote sold to us. They are not interested to do the right things at the start and would rather waste time and resources patching up on the backend after rolling out to impress the higher ups. Low quality work wrap with pretty packagings and ribbons. Pathetic.
Click to expand...
Sounds like you’re lapping it up.
 












I think it's going to get really ugly very quickly come the beginning of 2025. I am hearing senior leadership quite concerned about 4Q revenue numbers, steeper budget cuts likely on the way.
 






anonymous said:
I think it's going to get really ugly very quickly come the beginning of 2025. I am hearing senior leadership quite concerned about 4Q revenue numbers, steeper budget cuts likely on the way.
Click to expand...
Still going strong with all the international travelings tho. All other pharma are on travel bans. We must still be doing well.
 












anonymous said:
currently yes, but in 2028 ketrudya off patten, that's a huge hit. That's why they are focused on cost cutting NOW
Click to expand...
Exactly! Merck is bracing for quite a hit in 2028- between 25 billion patent cliff for Keytruda AND the 8.9 billion cliff that same year for Gardasil 9, there will be significant impact to the company. And I’m not sure that we have any real blockbusters in the clinical. I don’t think there’s any other pharma company facing anything close to us in the next decade. They are staggering numbers. This, coupled by lower than expected growth for Gardasil in China (reflected in stock slump)… it’s no wonder that the bean counters are nervous!
 






Top Bottom
Back
Quote